Syed Mohi Ahmed, MD, PhD

a man is standing on a bus holding onto a railing . ALT: a man is standing on a bus holding onto a railing .

Pop quiz, hot shot ...

"Baseline PSMA-TTV is prognostic for overall survival and predictive for a beneficial effect on overall survival with the addition of [177Lu]Lu-PSMA-617 to enz as first-line treatment for high-risk metastatic CRPC. By contrast, PSMA SUVmean was not prognostic for PSA progression-free survival or OS"

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer | NEJM On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal junctio...

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

FDA Approval: Sunvozertinib in EGFR Exon 20 NSCLC | IASLC In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses EGFR exon 20 insertions and the recently approved targeted therapy for this subset of ...

What does the FDA approval of sunvozertinib mean for patients with EGFR exon 20 insertions? In this week’s #LungCancerConsidered, @stephenvliu.bsky.social talks with Dr. Mariam Alexander and Dr. James Chih-Hsin Yang about the newest EGFR-targeted therapy.

🎧 bit.ly/FDAexon20

Trastuzumab Deruxtecan in HER2-Positive Gastric Cancer | NEJM Quick Take Video Summary from The New England Journal of Medicine — Trastuzumab Deruxtecan in HER2-Positive Gastric Cancer

DESTINY-Gastric04 trial: Patients with HER2-positive metastatic gastric cancer have limited options after trastuzumab-based treatment. New phase 3 data show longer survival with trastuzumab deruxtecan than with standard second-line chemotherapy. nej.md/46HZ7W3

#MedSky #Oncology

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | NEJM Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain hig...

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

Taletrectinib in <i>ROS1</i>+ Non–Small Cell Lung Cancer: TRUST PURPOSETaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI). We report integrated efficacy and safety from registrational taletrectinib studies...

Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...

An illustration of zongertinib for treating patients with HER2-mutant non–small-cell lung cancer.

Beamion LUNG-1 trial: Safe, effective, oral therapies are needed for patients with HER2-mutant non–small-cell lung cancer. Research findings on the oral, irreversible, HER2-selective tyrosine kinase inhibitor zongertinib are summarized in a new Quick Take video. nej.md/3HETKwj

#MedSky

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer | NEJM The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unc...

In the KEYNOTE-689 phase 3 trial, the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved event-free survival among participants with locally advanced head and neck cancer without affecting surgical outcomes. Full trial results: nej.md/45X0Nuc

#MedSky #Oncology

In high-risk cutaneous squamous-cell carcinoma, adjuvant cemiplimab prolonged disease-free survival and reduced recurrence risk as compared with placebo. No new safety concerns with cemiplimab were seen. Full C-POST phase 3 trial results: nej.md/45kvdWR

#ASCO25 @ascocancer.bsky.social

DeLLphi-304: Among patients with relapsed small-cell lung cancer after the failure of platinum-based chemotherapy, tarlatamab therapy led to a greater overall and progression-free survival benefit over chemotherapy, with fewer severe adverse events. nej.md/3YWiy8O
 
#ASCO25

In non–small-cell lung cancer, three cycles of neoadjuvant nivolumab plus chemotherapy improved 5-year overall survival over chemotherapy alone, with variation according to pathological response. Full CheckMate 816 phase 3 trial results: nej.md/4k6Wlxj

#ASCO25 @ascocancer.bsky.social

Just presented at #ASCO25: Initial DESTINY-Breast09 results show 1L treatment w/ T-DXd + pertuzumab extends PFS by > 1 year compared w/ SOC THP: dailynews.ascopubs.org/do/destiny-b... #ASCODailyNews #BreastCancer #bcsm @danafarber.bsky.social @danafarbernews.bsky.social

In newly diagnosed myeloma, ASCT showed no benefit over chemotherapy in patients without postinduction measurable residual disease, and tandem ASCT was not more effective than single ASCT in those with postinduction MRD. Full MIDAS trial results: nej.md/4mkaecR
 
#ASCO25

statistically and clinically significant OS benefit at 5 y for a resectable solid tumor. Pts with pCR with neoadjuvant NIVO + chemo had a ~90% reduction in their risk of death by 5 y compared with those without pCR.

IRONMAN validating the poor prognosis of mHSPC with PSA>0.2 after 6-12 months ADT-ARPI and these patients could be targeted for intensification in future trials. PSA<0.02 at 6-12 m defines the best prognosis and may be of interest for de-intensification strategies.

meetings.asco.org/abstracts-pr...

Randomized, double-blind, Phase 3 trial, CAN-2409 significantly reduced the risk of PrCa recurrence or death when added to SoC EBRT+/- ADT.

CAN-2409: replication-defective adenovirus encoding the HSV-tk gene that, when combined with valacyclovir (prodrug), results in immunogenic cell death

NIAGARA and ctDNA
- ctDNA+ status at pre-RC was associated with non-pCR.
- Perioperative Durva provided an EFS benefit to both pts with ctDNA+ and ctDNA− status at baseline
- similar trend was observed with DFS based on ctDNA status post-RC

meetings.asco.org/abstracts-pr...

Looking forward to #ASCO25. I tried to summarise it, but there’s some really exciting new data.

#Bladder new ADCs strategies, pt selection, ctDNA, non-UC subtypes, RT + IO.
#Kidney biomarkers, new TKI & HIFi, nccRCC
#Prostate new drugs, pt selection, aggressive variants.

What an incredible privilege to sit at the feet of Larry Einhorn as he casts pearls in a continuous shower from the podium before whatever animal I am. What this man does not know about #GermCellCancer #tcsm is probably not worth knowing. Watch his #ASCO25 talk online.

"The DeLLphi-304 trial showed tarlatamab significantly improved OS, PFS, and PROs, with a favorable safety and tolerability profile compared to CTx in pts with SCLC that progressed on or after initial platinum-based CTx, defining a new standard of care for these patients."

Who might benefit from prolonged osi?

MRD+ preceded DFS events in most pts with a median lead time of 4.7 mos across both arms. MRD– was maintained for most pts during adj osi tx with the majority of MRD/DFS events occurring after osi tx completion.

meetings.asco.org/abstracts-pr...

SWOG/NRG S1914: Randomized phase III trial of induction/consolidation atezolizumab + SBRT vs SBRT alone in high risk, early-stage NSCLC.

Immunotherapy (IO) added to SBRT in early-stage NSCLC, IO failed to improve survival. More G ≥3 adverse events were reported with AS

NEOADAURA: Neoadj osi with or without CT showed statistically significant improvement in the MPR rate over CT alone. EFS data were immature ...

meetings.asco.org/abstracts-pr...

Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.

(Due for release on June 2)

meetings.asco.org/abstracts-pr...

Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.

(Due for release on June 2)

meetings.asco.org/abstracts-pr...

IMforte met both primary endpoints of IRF-PFS and OS, demonstrating a clinically meaningful benefit with 1L maintenance tx with lurbi + atezo vs atezo in pts with ES-SCLC.

meetings.asco.org/abstracts-pr...

"In pts with PV rusfertide resulted in ... reduction in the mean number of phlebotomies and improved Hct control. first agent to target the hepcidin pathway to control Hct and ... demonstrate a statistically significant improvement in the PROMIS Fatigue SF-8a and MFSAF PROs in pts with PV."

"Adjuvant NIVO added to CRT after surgery provided a statistically and clinically meaningful DFS improvement in PD-L1 all-comers patients. This is the first time in over 2 decades that a therapy demonstrated superiority over SOC CRT in patients with resected LA-SCCHN at high-risk of relapse."

First up at #ASCO25 Plenary: According to ATOMIC results, adding atezo to FOLFOX improves DFS in stage III dMMR #ColonCancer & yields 50% reduction in the risk of recurrence & death vs chemo alone: brnw.ch/21wT4N9 #ASCODailyNews